Blood glutamate scavenging as a novel glutamate-based therapeutic approach for post-stroke depression

Benjamin F. Gruenbaum, Ruslan Kutz, Alexander Zlotnik and Matthew Boyko

Abstract: Post-stroke depression (PSD) is a major complication of stroke that significantly impacts functional recovery and quality of life. While the exact mechanism of PSD is unknown, recent attention has focused on the association of the glutamatergic system in its etiology and treatment. Minimizing secondary brain damage and neuropsychiatric consequences associated with excess glutamate concentrations is a vital part of stroke management. The blood glutamate scavengers, oxaloacetate and pyruvate, degrade glutamate in the blood to its inactive metabolite, 2-ketoglutarate, by the coenzymes glutamate–oxaloacetate transaminase (GOT) and glutamate–pyruvate transaminase (GPT), respectively. This reduction in blood glutamate concentrations leads to a subsequent shift of glutamate down its concentration gradient from the blood to the brain, thereby decreasing brain glutamate levels. Although there are not yet any human trials that support blood glutamate scavengers for clinical use, there is increasing evidence from animal research of their efficacy as a promising new therapeutic approach for PSD. In this review, we present recent evidence in the literature of the potential therapeutic benefits of blood glutamate scavengers for reducing PSD and other related neuropsychiatric conditions. The evidence reviewed here should be useful in guiding future clinical trials.

Keywords: blood glutamate scavenging, glutamate, post-stroke depression, treatment

Introduction

Post-stroke depression (PSD) is a major and frequent consequence of stroke, associated with an increase in morbidity and mortality.1–4 Although the precise prevalence of PSD is hard to ascertain, estimates range from 20% to 60%.5,6 Despite its debilitating effects on patients’ recovery and quality of life, there remains no reliable and universal treatment for PSD. Historically, most antidepressant therapeutics influence serotoninergic, adrenergic, and/or dopaminergic systems with the aim of increasing synaptic availability of serotonin, norepinephrine, and dopamine. However, more recent studies have investigated the involvement of the glutamatergic system in the etiology and treatment of depression.

Glutamate is a nonessential amino acid that accounts for approximately 60% of all neurotransmitter activity. During stroke, glutamate concentrations in the brain’s extracerebral fluid and cerebrospinal fluid (CSF) increase 300–400-fold.7–11 As a result, the glutamate spreads, causing neuronal damage to areas beyond the infarcted tissue.12 Glutamate receptors are stimulated by the excess glutamate and lead to cell swelling, apoptosis, and neuronal death, with subsequent poor neurological outcomes.13–15 The glutamatergic system similarly plays a critical role in many mood disorders, such as depression, anxiety, dementia, and other psychiatric diseases.16–54 Ample evidence in the literature suggests that the next generation of antidepressants will consist of substances centered around the glutamate system.55 Limiting the secondary brain damage accompanied by excess glutamate concentrations post-brain injury is a vital part of stroke management.

A promising method involves the administration of intravenous pyruvate and oxaloacetate, called...
‘blood glutamate scavengers’ (BGS) which have demonstrated reductions in brain glutamate concentrations. In recent years, BGS have been gaining attention in the scientific community and have been extensively examined in a wide variety of neurologic and psychiatric animal models. This review discusses recent evidence in the literature for the potential therapeutic benefits of BGS for reducing PSD and other related neuropsychiatric conditions. Although clinical human trials have not yet taken place, the efficacy of BGS in limiting depressive-like symptoms following stroke has been shown in rodents. Unlike existing methods for treating PSD, the ability of BGS to reduce brain glutamate levels can potentially cease PSD development by targeting both the psychiatric and neurologic pathology.

The impact and burden
Stroke is often a devastating event, suffered by over 16 million people globally each year, and is a leading cause of death and disability. One third of cases lead to death, and another third to permanent disability. Stroke is a major contributor to acute hospitalizations for neurological conditions. Depression and anxiety disorders are the most common psychiatric conditions that appear post-stroke; however, many experience other psychotic symptoms, including hallucinations, delusions, and manic symptoms.

PSD is often overlooked and untreated, though it can have a serious, long-lasting impact on recovery and quality of life. It is estimated that PSD can appear in 30–35% of patients, with a range of 20–60%. Recently, it has been found that greater than 50% of rats developed mental and behavioral disorders after stroke and subarachnoid hemorrhage. The highest prevalence occurs between six months and two years following stroke, and the condition is accompanied by more acute physical and cognitive impairments, impaired quality of life, and an increased mortality. The rate of anxiety in the first 6 months after stroke varies between 22% and 25%. Another common neuropsychiatric complication of stroke is delirium, considered a major complication. In clinical studies, delirium in the acute period of stroke occurs 19% to 48% of the time, and the rate of post-stroke dementia is 6–32%. Post-stroke emotional incontinence (PSEI) affects between 11% and 52% of all stroke survivors. It is typically observed within a few weeks following stroke, persists from 1 week to a few years, and makes clinical treatment difficult. Most often, patients with PSEI present with bouts of laughter, crying, or both, that are uncontrollable, without any perceivable stimulus or initiated by minor, nonspecific stimuli. PSEI can cause patients distress and embarrassment, as well as social difficulties, and may interfere with the rehabilitation process due to the irritability and impulsiveness of the patients.

All of these deleterious side effects lead to enormous financial burden. Stroke costs the United States and European Union an estimated $34 billion and €45 billion, respectively, each year. Considering the modest arsenal of medical approaches for the treatment of PSD and behavior-related complications, we believe that the utilization of new therapeutic options in the form of glutamate scavengers may have enormous benefits to improve quality of life for stroke survivors.

Nonglutamate mechanisms of post-stroke psychiatric complications
The basis of PSD and other psychiatric complications of stroke remain largely unknown, with many theories linking their mechanisms to other, similar mechanisms known to be associated with depressive symptoms. Yet, as will be seen, these models are imperfect, given the specific cause of PSD compared with other depressive conditions.

Monoamine hypothesis
The monoamine hypothesis suggests that disruption in the synaptic availability of neurotransmitters, including serotonin, dopamine, and norepinephrine, are largely responsible for depressive behavior and other psychiatric symptoms. Patients with PSD have been found to have significant reductions in levels of both serum and CSF serotonin. A common treatment for depression, including PSD, involves decreasing the reuptake of serotonin through amino–neurotransmitter drugs like selective serotonin reuptake inhibitors (SSRIs), and serotonin and norepinephrine reuptake inhibitors (SNRIs).

Vascular depression theory
Some evidence suggests that vascular depression caused by cardiovascular disease might contribute to the pathogenesis of PSD. This theory
suggests that cerebral lesions disrupt critical areas in the brain that lead to symptoms of depression. Hypertension after stroke has been shown to result in depressive symptoms, and homocysteine, a risk factor for vascular disease, has also been studied for its possible association with PSD.

**Neurogenesis hypothesis**
Alternatively, the neurogenic hypothesis suggests that depression may be related to an impairment in neurogenesis, the brain’s capacity to produce new neurons. This hypothesis bases itself on studies of people with depression or animals exhibiting depressive-like symptoms with decreased neurogenesis and hippocampal volume. Furthermore, studies have shown that antidepressants enhance the neurogenesis of hippocampus.

**Activation of the hypothalamic–pituitary–adrenal axis**
PSD is associated with increased cortisol levels, yet the specific pathogenesis of hypercortisolism-related depression remains unknown. Like other stressors, the stress from stroke may cause activation of the hypothalamic–pituitary–adrenal axis. There is also evidence, however, that hypercortisolism may be related to cytokine activity with or without monoamine dysfunction.

**Estrogen and progesterone theory**
The hormone estrogen has been implicated in depressive disorder. Similarities between estrogen and brain-derived neurotrophic factor, which is associated with PSD, suggest that estrogen replacement therapy would be a proper treatment for PSD.

**Immune dysfunction hypothesis**
A substantial volume of evidence shows that depression may be partly attributable to dysfunction of the immune system. While the specific mechanisms on the molecular and cellular level remains unclear, this theory proposes that PSD may be related to an overly activated inflammatory response leading to inflammation-bound cell death in areas of the brain involved in mood. During PSD, there is an increase in numerous inflammatory markers, pro-inflammatory cytokines, and pre-inflammatory/anti-inflammatory ratios with reduced complementary expression.

**Glutamate mechanisms of post-stroke psychiatric complications**
There is increasing evidence from the past few years that the glutamatergic system plays a crucial role in the development of mental disorders. Glutamate levels have been shown to contribute to depression, anxiety, and dementia among other psychiatric diseases.

Alterations in glutamate levels have been described in the blood and CSF of patients with major depression disorder (MDD). Plasma glutamate levels are associated with the severity of depressive symptoms. Frontal cortex postmortem human tissue has been shown to have increased glutamate levels in those with a history of depression-compared controls. Magnetic resonance spectroscopy (MRS) facilitates simultaneous in vivo glutamate measurements, and the observed regional changes in glutamate provide the most promising evidence of an association between glutamate and depression. These studies have revealed increased levels of brain glutamate of patients with MDD and patients with PSD.

**Current approaches for the treatment of PSD**
The previous section demonstrated mechanisms of PSD which often parallel other depressive conditions. Since PSD remains difficult to manage and treatment often fails, current therapeutic approaches for this condition have been of great interest (Table 1). While historically, treatment for PSD targeted the γ-aminobutyric acid or serotonergic neurotransmitter systems, recent therapeutic modalities have focused on the role of the glutamatergic system.

**Nonglutamate-based antidepressants**
Treatments that target the γ-aminobutyric acid or serotonergic system, such as benzodiazepines and SSRIs, respectively, are the most commonly utilized therapy for anxiety, depression, stress, and trauma-related disorders. However, only 50–60% of patients treated for depression and anxiety with antidepressants respond to this therapy. PSD can often be treated with SSRIs, SNRIs, monoamine-oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), norepinephrine and dopamine reuptake inhibitors, other serotonergic antidepressants, as well as stimulants.
and even electroconvulsive therapy. These treatments are not universally effective. A recent randomized controlled trial showed that the SSRI, sertraline (Zoloft), was no more effective than placebo in treating people with depression following traumatic brain injury (TBI). Due to the high prevalence of post-TBI and PSD, finding a solution that specifically targets these neuropsychiatric conditions is optimal.

Glutamate-based antidepressants

The antidepressant-like effects of glutamatergic agents have recently become more widely studied and applied to the treatment of various mood disorders. Recent clinical studies have illustrated the effectiveness of glutamatergic agents for the treatment of PSD, obsessive–compulsive disorder, post-traumatic stress disorder, generalized anxiety disorder, and social phobia. It is thought that the efficacy of these drugs reflects the impact of glutamate in the development of mental disorders. Here, we summarize the known antidepressant properties of various therapeutic agents that act on the glutamatergic system.

N-methyl-D-aspartate receptor antagonists

There are many clinical studies that have revealed antidepressive effects of drugs that antagonize the N-methyl-D-aspartate receptor (NMDA) receptor. Recent evidence has determined the rapid antidepressive effects of ketamine, which interferes with glutamate receptor activation in patients with treatment-resistant MDD.

| Therapeutic targets | Advantages | Disadvantages |
|---------------------|------------|---------------|
| NMDA-receptor antagonists | Antidepressive effects | Associated with positive neurological outcome in animal models | Associated with poor neurological outcome, cardiovascular disease, and mortality in clinical studies Decreases normal glutamate activity within and outside of the brain |
| AMPA-receptor antagonists | Antidepressive effects | | Decreases normal glutamate activity within and outside of the brain Limited clinical trials |
| BGS (pyruvate, oxaloacetate) | Antidepressive effects Maintains neuronal integrity Associated with positive neurological outcome Inexpensive Ability to maintain functional glutamate levels | | Lacking clinical studies |
| Other (glutamate-transporter mediated, mGluRs antagonists, minocycline, riluzole) | Antidepressive effects | | Decreases normal glutamate activity within and outside of the brain Limited clinical trials |

AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; BGS, blood glutamate scavengers; MAOls, monoamine-oxidase inhibitors; mGluRs, metabotropic glutamate receptors; NDRIs, norepinephrine and dopamine reuptake inhibitors; NMDA, N-methyl-D-aspartate receptor; SNRIs, serotonin and norepinephrine reuptake inhibitors; SSRIs, selective serotonin reuptake inhibitors; TCAs, tricyclic antidepressants.
The robust and now widely accepted antidepressant effects of NMDA receptor antagonists have led to the development of other agents targeting the same receptor, including Ro25-6981, CP-101,606, memantine, magnesium, MK-0657, AZD6765, traxoprodil, NRX-1047, GLYX-13, D-cycloserine, zinc, MK-801, and CGP37849. Recently, the US Food and Drug Administration has approved the NMDA receptor antagonist esketamine for patients with treatment-resistant depression.

α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonists
At least six agents that target α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors have been observed as potential therapies for depression: aniracetam, piracetam, ampakines, CX614, LY392098, and LY451646.

Metabotropic glutamate receptors
Glutamatergic transmission is controlled by ionotropic and by metabotropic glutamate receptors (mGluRs). Recent studies have shown that antagonism of mGluRs lead to antidepressant action in mGluR1 and mGluR5 (group I); mGluR2 and mGluR3 (group II); and mGluR4, mGluR6, mGluR7, and mGluR8 (group III).

Glutamate transporters
Antidepressant activity has been demonstrated not only from agents that modulate the glutamatergic synapse, but also in those that modify glutamate transporters responsible for extracellular glutamate uptake. There is evidence for the roles of glutamate transporter 1 and excitatory amino acid transporter 2 on depression.

Other
Other glutamatergic drugs have antidepressant-like effects, including minocycline and riluzole. Minocycline is a metabolic pathway of the essential amino acid L-tryptophan, which may cause NMDA-receptor activity in the brain. Riluzole is an NMDA, AMPA, and kainate receptor antagonist that prevents the emission of presynaptic glutamate and facilitates the uptake of glial glutamate at relatively high concentrations.

Problems
Although glutamate receptor antagonists have been shown effective for treatment of depressive symptoms in both preclinical and clinical studies, their efficacy in preclinical studies to improve neurologic outcomes after stroke and other neurologic insults has not been replicated in human trials. Following stroke and TBI, clinical studies of NMDA receptor antagonists led to an increase in the neurological severity outcomes and mortality rate. Complications of these studies included premature death, cardiovascular issues, and development of psychoses, likely due to the harmful impact on the function of normal physiologic glutamate receptors in both healthy brain tissue and areas at risk of stroke-related injury. At normal levels, glutamate plays a crucial role in maintaining neuronal function and communication through the activation of NMDA-receptor signal pathways. Agents that block NMDA receptors do not differentiate between the positive and negative consequences of NMDA signal dysfunction. In addition, glutamate antagonists target glutamate transporters that are found in other areas of the body outside the brain, such as in the pancreas, that are important for the metabolic regulation of glutamate. It is likely that NMDA-receptor antagonists have a negative effect on metabolic processes throughout the body.

BGS with oxaloacetate and pyruvate as an alternative method
BGS likely does not display the same detrimental effects of the other receptor antagonists, which would make it a better treatment option for the same conditions (Table 1). Over the past two decades, studies have shown a link between the mechanisms of depression and disruptions to the glutamatergic system, and determined that this system provides a central focal point from which to develop new antidepressant treatments.

The brain uses several techniques to rid itself of excess glutamate. Initial studies on potential therapeutic modalities focused on antagonizing glutamate receptors, as described above. However, a novel approach consists of removing only excess glutamate in the brain by utilization of BGS in the form of oxaloacetate and pyruvate. This is achieved through facilitating the body’s natural brain-to-blood glutamate efflux down its concentration gradient. Glutamate is metabolized in the blood to its inactive metabolite, 2-ketoglutarate, by the enzymes
GOT and GPT in the presence of their cosubstrates, oxaloacetate and pyruvate, respectively. By administering oxaloacetate and pyruvate peripherally, blood-glutamate scavenging can occur through several processes, such as catalyzation of enzymes responsible for glutamate metabolism, glutamate redistribution into tissue, and the acute stress response. This approach has been validated by several animal studies.

Unlike NMDA-receptor antagonists, BGS do not interfere with glutamate receptors or glutamate-mediated synaptic activity. Rather, BGS eradicate only the pathologically elevated levels of glutamate in cerebral fluid without eliminating glutamate levels entirely. This process of glutamate efflux is self-limiting, slowing and eventually stopping when glutamate concentrations are decreased enough to no longer support glutamate transportation.

The reduction of blood glutamate levels leads to the formation of a concentration gradient of glutamate between the brain and blood that favors glutamate efflux, thereby prompting the transport of excess glutamate from the brain’s extracellular fluid (ECF) to the blood. Thus, lowering glutamate levels restricts secondary brain injury associated with glutamate neurotoxicity. Moreover, the reduction of glutamate in the blood circulation assists with neurological outcome after TBI and stroke.

Clinical studies have demonstrated an association between low GOT levels and poor neurological outcome post-stroke; while high GOT levels are associated with better neurological outcome. GOT and GPT cause a reduction in glutamate levels both in the brain ECF and in the blood, and both have been used for successful treatment in animal models of TBI and stroke.

Due to its ability to limit secondary effects of stroke, BGS potentially provide a treatment option for PSD by targeting both the effects of stroke on neurological function and on resultant depression. Recent support for the role of BGS as a therapeutic modality in PSD was demonstrated in a rodent model showing that administration of pyruvate lowered glutamate levels, and improved neurological outcome and post-stroke depressive behavior. In this study, 80 rats were randomly separated into one of three groups: middle cerebral artery occlusion (MCAO) plus pyruvate treatment, MCAO and treatment with placebo, and a control group. The rats in the first group showed significant reduction of lesion volume, brain edema and blood–brain barrier breakdown compared with rats who had MCAO with placebo, and displayed fewer depressive-like behaviors.

Therefore, there is growing evidence that BGS may be advantageous as a therapeutic option for PSD due to their ability to maintain the physiological effects of glutamate, allowing for its continued preservation of the metabolic and electrolyte balance, and neuronal function, and its benefits for neurological recovery after brain injury. BGS possess the ability to maintain equilibrium between minimizing the negative effects of excess glutamate and keeping its positive effects that are essential for life.

Conclusion
Stroke itself has debilitating effects on neurological function, and additional complications such as PSD make treatment of stroke challenging. Current treatment for PSD is often insufficient, but the therapeutic role of glutamatergic agents has been encouraging. Collectively, experimental evidence with BGS has shown much promise in the treatment of PSD. Clinical trials are a requisite future action to studying the clinical effects of BGS for the treatment of PSD in humans. A better understanding of the relationship between glutamate and BGS will produce critical insights that will be indispensable for the advancement of the clinical diagnosis, prognosis, and treatment of PSD.

Acknowledgements
Benjamin F. Gruenbaum and Ruslan Kutz contributed equally to this work.

Funding
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: support was provided by a grant (No. 1490/15) from the Israel Science Foundation to Matthew Boyko and Alexander Zlotnik.

Conflict of interest statement
The authors declare that there is no conflict of interest.

ORCID iD
Matthew Boyko https://orcid.org/0000-0003-3116-1643
References
1. Astrom M, Adolfsson R and Asplund K. Major depression in stroke patients: a three year longitudinal study. *Stroke* 1993; 24: 976–982.
2. Eastwood MR, Rifat SL, Nobbs H, et al. Mood disorder following cerebrovascular accident. *Br J Psychiatry* 1989; 154: 195–200.
3. Robinson R, Bolduc P and Price T. Two-year longitudinal study of poststroke mood disorders: diagnosis and outcome at one and two years. *Stroke* 1987; 18: 837–843.
4. Feng C, Fang M and Liu XY. The neurobiological pathogenesis of poststroke depression. *ScientificWorldJournal* 2014; 2014: 521349.
5. Lenzi GL, Altieri M and Maestrini I. Post-stroke depression. *Rev Neurol (Paris)* 2008; 164: 837–840.
6. Dafer RM, Rao M, Shareef A, et al. Poststroke depression. *Top Stroke Rehabil* 2008; 15: 13–21.
7. Castillo J, Davalos A, Alvarez-Sabin J, et al. Molecular signatures of brain injury after intracerebral hemorrhage. *Neurology* 2002; 58: 624–629.
8. Castillo J, Davalos A, Naveiro J, et al. Neuroexcitatory amino acids and their relation to infarct size and neurological deficit in ischemic stroke. *Stroke* 1996; 27: 1060–1065.
9. Castillo J, Davalos A and Noya M. Progression of ischaemic stroke and excitotoxic aminoacids. *Lancet* 1997; 349: 79–83.
10. Guyot LL, Diaz FG, O'Regan MH, et al. Real-time measurement of glutamate release from the ischemic penumbra of the rat cerebral cortex using a focal middle cerebral artery occlusion model. *Neurosci Lett* 2001; 299: 37–40.
11. Benveniste H, Drejer J, Schousboe A, et al. Elevation of the extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis. *J Neurochem* 1984; 43: 1369–1374.
12. Han F, Shiota N, Moriguchi S, et al. Downregulation of glutamate transporters is associated with elevation in extracellular glutamate concentration following rat microsphere embolism. *Neurosci Lett* 2008; 430: 275–280.
13. Koura SS, Doppenberg EM, Marmarou A, et al. Relationship between excitatory amino acid release and outcome after severe human head injury. *Acta Neurochir Suppl* 1998; 71: 244–246.
14. Zaunder A, Bullock R, Kuta AJ, et al. Glutamate release and cerebral blood flow after severe human head injury. *Acta Neurochir Suppl* 1996; 67: 40–44.
15. Zhang H, Zhang X, Zhang T, et al. Excitatory amino acids in cerebrospinal fluid of patients with acute head injuries. *Clin Chem* 2001; 47: 1458–1462.
16. McCarthy DJ, Alexander R, Smith MA, et al. Glutamate-based depression GBD. *Med Hypotheses* 2012; 78: 675–681.
17. Sanacora G, Treccani G and Popoli M. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. *Neuropharmacology* 2012; 62: 63–77.
18. Tokita K, Yamaji T and Hashimoto K. Roles of glutamate signaling in preclinical and/or mechanistic models of depression. *Pharmacol Biochem Behav* 2012; 100: 688–704.
19. Mitchell ND and Baker GB. An update on the role of glutamate in the pathophysiology of depression. *Acta Psychiatr Scand* 2010; 122: 192–210.
20. Riaza Bermudo-Soriano C, Perez-Rodriguez MM, Vaquero-Lorenzo C, et al. New perspectives in glutamate and anxiety. *Pharmacol Biochem Behav* 2012; 100: 752–774.
21. Cortese BM and Phan KL. The role of glutamate in anxiety and related disorders. *CNS Spectr* 2005; 10: 820–830.
22. Amiel JM and Mathew SJ. Glutamate and anxiety disorders. *Curr Psychiatry Rep* 2007; 9: 278–283.
23. Cosman KM and Porsteinsson AP. Glutamate in the neurobiology and treatment of dementias. *Primary Psychiatry* 2006; 13: 48.
24. Butterfield DA and Pocernich CB. The glutamatergic system and Alzheimer’s disease: therapeutic implications. *CNS Drugs* 2003; 17: 641–652.
25. Francis PT. Glutamatergic systems in Alzheimer’s disease. *Int J Geriatr Psychiatry* 2003; 18(Suppl. 1): S15–S21.
26. Krystal JH, Sanacora G, Blumberg H, et al. Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. *Mol Psychiatry* 2002; 7(Suppl. 1): S71–S80.
27. Maeng S and Zarate CA Jr. The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects. *Curr Psychiatry Rep* 2007; 9: 467–474.
28. Palucha A and Pilk A. Metabotropic glutamate receptor ligands as possible anxiolytic and
antidepressant drugs. *Pharmacol Ther* 2007; 115: 116–147.

29. Pilc A, Chaki S, Nowak G, *et al.* Mood disorders: regulation by metabotropic glutamate receptors. *Biochim Pharmacol* 2008; 75: 997–1006.

30. Pittenger C, Sanacora G and Krystal JH. The NMDA receptor as a therapeutic target in major depressive disorder. *CNS Neurol Disord Drug Targets* 2007; 6: 101–115.

31. Sanacora G, Rothman DL, Mason G, *et al.* Clinical studies implementing glutamate neurotransmission in mood disorders. *Ann N Y Acad Sci* 2003; 1003: 292–308.

32. Sen S and Sanacora G. Major depression: emerging therapeutics. *Mt Sinai J Med* 2008; 75: 204–225.

33. Swanson CJ, Bures M, Johnson MP, *et al.* Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. *Nat Rev Drug Discov* 2005; 4: 131–144.

34. Waschkies CF, Bruns A, Muller S, *et al.* Neuropharmacological and neurobiological relevance of in vivo ¹H-MRS of GABA and glutamate for preclinical drug discovery in mental disorders. *Neuropsychopharmacology* 2014; 39: 2331–2339.

35. Witkin JM, Marek GJ, Johnson BG, *et al.* Metabotropic glutamate receptors in the control of mood disorders. *CNS Neurol Disord Drug Targets* 2007; 6: 87–100.

36. Hashimoto K, Sawa A and Iyo M. Increased levels of glutamate in brains from patients with mood disorders. *Biol Psychiatry* 2007; 62: 1310–1316.

37. Levine J, Panchalingam K, Rapoport A, *et al.* Increased cerebrospinal fluid glutamine levels in depressed patients. *Biol Psychiatry* 2000; 47: 586–593.

38. Mauri MC, Ferrara A, Boscati L, *et al.* Plasma and platelet amino acid concentrations in patients affected by major depression and under fluvoxamine treatment. *Neuropsychobiology* 1998; 37: 124–129.

39. Mitani H, Shirayama Y, Yamada T, *et al.* Correlation between plasma levels of glutamate, alanine and serine with severity of depression. *Prog Neuropsychopharmacol Biol Psychiatry* 2006; 30: 1155–1158.

40. Altamura C, Maes M, Dai J, *et al.* Plasma concentrations of excitatory amino acids, serine, glycine, taurine and histidine in major depression. *Eur Neuropsychopharmacol* 1995; 5(Suppl): 71–75.

41. Kucukibrahimoglu E, Saygin MZ, Caliskan M, *et al.* The change in plasma GABA, glutamine and glutamate levels in fluoxetine- or S-citalopram-treated female patients with major depression. *Eur J Clin Pharmacol* 2009; 65: 571–577.

42. Zarate C Jr, Machado-Vieira R, Henter I, *et al.* Glutamatergic modulators: the future of treating mood disorders? *Harv Rev Psychiatry* 2010; 18: 293–303.

43. Fountoulakis KN. The possible involvement of NMDA glutamate receptor in the etiopathogenesis of bipolar disorder. *Curr Pharm Des* 2012; 18: 1605–1608.

44. Machado-Vieira R, Ibrahim L, Henter ID, *et al.* Novel glutamatergic agents for major depressive disorder and bipolar disorder. *Pharmacol Biochem Behav* 2012; 100: 678–687.

45. Machado-Vieira R, Salvadore G, Ibrahim LA, *et al.* Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders. *Curr Pharm Des* 2009; 15: 1595–1611.

46. Ghanizadeh A. Increased glutamate and homocysteine and decreased glutamine levels in autism: a review and strategies for future studies of amino acids in autism. *Dis Markers* 2013; 35: 281–286.

47. Coulter DA and Eid T. Astrocytic regulation of glutamate homeostasis in epilepsy. *Glia* 2012; 60: 1215–1226.

48. Carrillo-Mora P, Silva-Adaya D and Villaseñor-Aguayo K. Glutamate in Parkinson’s disease: role of antiglutamatergic drugs. *Basal Ganglia* 2013; 3: 147–157.

49. Vikelis M and Mitsikostas DD. The role of glutamate and its receptors in migraine. *CNS Neurol Disord Drug Targets* 2007; 6: 251–257.

50. Javitt DC. Glutamatergic theories of schizophrenia. *Isr J Psychiatry Relat Sci* 2010; 47: 4–16.

51. Wu K, Hanna GL, Rosenberg DR, *et al.* The role of glutamate signaling in the pathogenesis and treatment of obsessive-compulsive disorder. *Pharmacol Biochem Behav* 2012; 100: 726–735.

52. Pittenger C, Bloch MH and Williams K. Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment. *Pharmacol Ther* 2011; 132: 314–332.
mood disorders. *Neuropsychiatr Dis Treat* 2013; 9: 1101–1112.

54. Javitt DC. Glutamate as a therapeutic target in psychiatric disorders. *Mol Psychiatry* 2004; 9: 984–997, 979.

55. Sanacora G, Zarate CA, Krystal JH, et al. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. *Nat Rev Drug Discov* 2008; 7: 426–437.

56. Gottlieb M, Wang Y and Teichberg VI. Blood-mediated scavenging of cerebrospinal fluid glutamate. *J Neurochem* 2003; 87: 119–126.

57. Frank D, Kuts R, Tsenter P, et al. The effect of pyruvate on the development and progression of post-stroke depression: a new therapeutic approach. *Neuropharmacology* 2019; 155: 173–184.

58. Warlow CP. Epidemiology of stroke. *Lancet* 1998; 352(Suppl. 3): SIII1–4.

59. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics–2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. *Circulation* 2009; 119: e21–e181.

60. Feigin VL, Norrving B and Mensah GA. Global burden of stroke. *Circ Res* 2017; 120: 439–448.

61. Feigin VL, Roth GA, Naghavi M, et al. Global burden of stroke and risk factors in 188 countries, during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet Neurol* 2016; 15: 913–924.

62. Bejot Y, Daubail B and Giroud M. Epidemiology of stroke and transient ischemic attacks: current knowledge and perspectives. *Rev Neurol (Paris)* 2016; 172: 59–68.

63. Thrift AG, Thayabaranathan T, Howard G, et al. Global stroke statistics. *Int J Stroke* 2017; 12: 13–32.

64. Hachinski V and Norris JW. The acute stroke. The University of Michigan: F.A. Davis, 1985.

65. Boyko M, Azab AN, Kuts R, et al. The neurobehavioral profile in rats after subarachnoid hemorrhage. *Brain Res* 2013; 1491: 109–116.

66. Boyko M, Kutz R, Gruenbaum BF, et al. The influence of aging on poststroke depression using a rat model via middle cerebral artery occlusion. *Cogn Affect Behav Neurosci* 2013; 13: 847–859.

67. Starkstein SE and Robinson RG. Psychiatric complications of stroke. In: Jests DV and Friedman JH (eds) *Psychiatry for neurologists. Current clinical neurology*. Totowa, NJ: Humana Press Inc., 2006, pp. 132–152.

68. De Wit L, Putman K, Baert I, et al. Anxiety and depression in the first six months after stroke. A longitudinal multicentre study. *Disabil Rehabil* 2008; 30: 1858–1866.

69. Melkas S, Laurila JV, Vataja R, et al. Post-stroke delirium in relation to dementia and long-term mortality. *Int J Geriatr Psychiatry* 2012; 27: 401–408.

70. Gustafson Y, Olsson T, Eriksson S, et al. Acute confusional states (delirium) in stroke patients. *Cerebrovasc Dis* 1991; 1: 257–264.

71. Schiffer R and Pope LE. Review of pseudobulbar affect including a novel and potential therapy. *J Neuropsychiatry Clin Neurosci* 2005; 17: 447–454.

72. Tang WK, Chan SS, Chiu HF, et al. Emotional incontinence in Chinese stroke patients—diagnosis, frequency, and clinical and radiological correlates. *J Neurol* 2004; 251: 865–869.

73. Kim JS. Pathologic laughter after unilateral stroke. *J Neurol Sci* 1997; 148: 121–125.

74. Ceccaldi M, Poncet M, Milandre L, et al. Temporary forced laughter after unilateral strokes. *Eur Neurol* 1994; 34: 36–39.

75. Dark FL, McGrath JJ and Ron MA. Pathological laughing and crying. *Aust N Z J Psychiatry* 1996; 30: 472–479.

76. Kim JS and Choi-Kwon S. Poststroke depression and emotional incontinence: correlation with lesion location. *Neurology* 2000; 54: 1805–1810.

77. Andersen G, Vestergaard K and Riis JO. Citalopram for post-stroke pathological crying. *Lancet* 1993; 342: 837–839.

78. Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. *Circulation* 2017; 135: e146–e603.

79. Wilkins E, Wilson L, Wickramasinghe K, et al. European cardiovascular disease statistics 2017. Brussels: European Heart Network, http://www.ehnheart.org/images/CVD-statistics-report-August-2017.pdf (2019, accessed 23 July, 2019)

80. Parker G and Brotchie H. Mood effects of the amino acids tryptophan and tyrosine: ‘Food for Thought’ III. *Acta Psychiatr Scand* 2011; 124: 417–426.

81. Winter C, Von Rumohr A, Mundt A, et al. Lesions of dopaminergic neurons in the substantia nigra pars compacta and in the ventral tegmental area enhance depressive-like
behavior in rats. Behav Brain Res 2007; 184: 133–141.

82. Robinson RG and Bloom FE. Pharmacological treatment following experimental cerebral infarction: implications for understanding psychological symptoms of human stroke. Biol Psychiatry 1977; 12: 669–680.

83. Gao HQ, Zhu HY, Zhang YQ, et al. Reduction of cerebrospinal fluid and plasma serotonin in patients with post-stroke depression: a preliminary report. Clin Invest Med 2008; 31: E351–E356.

84. Santos M, Kovari E, Gold G, et al. The neuroanatomical model of post-stroke depression: towards a change of focus? J Neurol Sci 2009; 283: 158–162.

85. Santos M, Kovari E, Hof PR, et al. The impact of vascular burden on late-life depression. Brain Res Rev 2009; 62: 19–32.

86. Hickie I, Scott E, Mitchell P, et al. Subcortical hyperintensities on magnetic resonance imaging: clinical correlates and prognostic significance in patients with severe depression. Biol Psychiatry 1995; 37: 151–160.

87. Salloway S, Malloy P, Kohn R, et al. MRI and neuropsychological differences in early- and late-life-onset geriatric depression. Neurology 1996; 46: 1567–1574.

88. Fujikawa T, Yamawaki S and Touhouda Y. Incidence of silent cerebral infarction in patients with major depression. Stroke 1993; 24: 1631–1634.

89. Krishnan KR, Hays JC and Blazer DG. MRI-defined vascular depression. Am J Psychiatry 1997; 154: 497–501.

90. Kim JT, Park MS, Yoon GJ, et al. White matter hyperintensity as a factor associated with delayed mood disorders in patients with acute ischemic stroke. Eur Neurol 2011; 66: 343–349.

91. Santos M, Gold G, Kovari E, et al. Differential impact of lacunes and microvascular lesions on poststroke depression. Stroke 2009; 40: 3557–3562.

92. Tennen G, Herrmann N, Black SE, et al. Are vascular risk factors associated with post-stroke depressive symptoms? J Geriatr Psychiatry Neurol 2011; 24: 215–221.

93. Pascoe MC, Crewther SG, Carey LM, et al. Homocysteine as a potential biochemical marker for depression in elderly stroke survivors. Food Nutr Res. Epub ahead of print 11 April 2012. DOI 10.3402/fnr.v56i0.14973.

94. Wang SH, Zhang ZJ, Guo YJ, et al. Hippocampal neurogenesis and behavioural studies on adult ischemic rat response to chronic mild stress. Behav Brain Res 2008; 189: 9–16.

95. Eisch AJ and Petrik D. Depression and hippocampal neurogenesis: a road to remission? Science 2012; 338: 72–75.

96. Astrom M, Olsson T and Asplund K. Different linkage of depression to hypercortisolism early versus late after stroke. A 3-year longitudinal study. Stroke 1993; 24: 52–57.

97. Zunszain PA, Anacker C, Cattaneo A, et al. Glucocorticoids, cytokines and brain abnormalities in depression. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 722–729.

98. Johansson A, Olsson T, Carlberg B, et al. Hypercortisolism after stroke—partly cytokine-mediated? J Neurol Sci 1997; 147: 43–47.

99. Reimold M, Knobel A, Rapp MA, et al. Central serotonin transporter levels are associated with stress hormone response and anxiety. Psychopharmacology (Berl) 2011; 213: 563–572.

100. Su Q, Cheng Y, Jin K, et al. Estrogen therapy increases BDNF expression and improves post-stroke depression in ovariectomy-treated rats. Exp Ther Med 2016; 12: 1843–1848.

101. Cheng Y, Su Q, Shao B, et al. 17 beta-estradiol attenuates poststroke depression and increases neurogenesis in female ovariectomized rats. Biomed Res Int 2013; 2013: 392434.

102. Leonard BE. The concept of depression as a dysfunction of the immune system. Currc Immunol Res 2010; 6: 205–212.

103. Maes M. The cytokine hypothesis of depression: inflammation, oxidative & nitrosative stress (IO&NS) and leaky gut as new targets for adjunctive treatments in depression. Neuro Endocrinol Lett 2008; 29: 287–291.

104. Becker KJ. Inflammation and the silent sequelae of stroke. Neurotherapeutics 2016; 13: 801–810.

105. Pascoe MC, Crewther SG, Carey LM, et al. Inflammation and depression: why poststroke depression may be the norm and not the exception. Int J Stroke 2011; 6: 128–135.

106. Levada OA and Troyan AS. Poststroke depression biomarkers: a narrative review. Front Neurol 2018; 9: 577.

107. Frye MA, Watzl J, Banakar S, et al. Increased anterior cingulate/medial prefrontal cortical glutamate and creatine in bipolar depression. Neuropsychopharmacol 2007; 32: 2490–2499.

108. Sanacora G, Gueorguieva R, Epperson CN, et al. Subtype-specific alterations of gamma-aminobutyric...
acid and glutamate in patients with major depression. Arch Gen Psychiatry 2004; 61: 705–713.

109. Glodzik-Sobanska L, Slowik A, McHugh P, et al. Single voxel proton magnetic resonance spectroscopy in post-stroke depression. Psychiatry Res 2006; 148: 111–120.

110. O’Leary OF, Dinan TG and Cryan JF. Faster, better, stronger: towards new antidepressant therapeutic strategies. Eur J Pharmacol 2015; 753: 32–50.

111. Shaffery J, Hoffmann R and Armitage R. The neurobiology of depression: perspectives from animal and human sleep studies. Neuroscientist 2003; 9: 82–98.

112. Andersen G, Vestergaard K and Lauritzen L. Effective treatment of poststroke depression with the selective serotonin reuptake inhibitor citalopram. Stroke 1994; 25: 1099–1104.

113. Currier M, Murray G and Welch C. Electroconvulsive therapy for poststroke depressed geriatric patients. J Neuropsychiatry Clin Neurosci 1992; 4: 140–144.

114. Robinson RG, Lipsey JR and Pearlson GD. The occurrence and treatment of poststroke mood disorders. Compr Ther 1984; 10: 19–24.

115. Wiart L, Petit H, Joseph PA, et al. Fluoxetine in early poststroke depression: a double-blind placebo-controlled study. Stroke 2000; 31: 1829–1832.

116. Fann JR, Bombardier CH, Temkin N, et al. Sertraline for major depression during the year following traumatic brain injury: a randomized controlled trial. J Head Trauma Rehabil 2017; 32: 332–342.

117. Hashimoto K. The role of glutamate on the action of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 1558–1568.

118. Pile A, Wieronska JM and Skolnick P. Glutamate-based antidepressants: preclinical psychopharmacology. Biol Psychiatry 2013; 73: 1125–1132.

119. Chakrabarty K, Bhattacharyya S, Christopher R, et al. Glutamatergic dysfunction in OCD. Neuropsychopharmacology 2005; 30: 1735–1740.

120. Douglas Bremner J, Mletzko T, Welter S, et al. Treatment of posttraumatic stress disorder with phenytoin: an open-label pilot study. J Clin Psychiatry 2004; 65: 1539–1564.

121. Heresco-Levy U, Kremer I, Javitt DC, et al. Pilot-controlled trial of D-cycloserine for the treatment of post-traumatic stress disorder. Int J Neuropsychopharmacol 2002; 5: 301–307.

122. Ressler KJ, Rothbaum BO, Tannenbaum L, et al. Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry 2004; 61: 1136–1144.

123. Berlant JL. Prospective open-label study of add-on and monotherapy topiramate in civilians with chronic nonhallucinatory posttraumatic stress disorder. BMC Psychiatry 2004; 4: 24.

124. Van Ameringen M, Mancini C, Pipe B, et al. An open trial of topiramate in the treatment of generalized social phobia. J Clin Psychiatry 2004; 65: 1674–1678.

125. Van Ameringen M, Mancini C, Pipe B, Oakman J and Bennett M. An open trial of topiramate in the treatment of generalized social phobia. J Clin Psychiatry 2004; 65: 1674–8.

126. Harvey BH and Shahid M. Metabotropic and ionotropic glutamate receptors as neurobiological targets in anxiety and stress-related disorders: focus on pharmacology and preclinical translational models. Pharmacol Biochem Behav 2012; 100: 775–800.

127. Hashimoto K. Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Res Rev 2009; 61: 105–123.

128. Paul IA and Skolnick P. Glutamate and depression: clinical and preclinical studies. Ann N Y Acad Sci 2003; 1003: 250–272.

129. Palucha A and Pile A. The involvement of glutamate in the pathophophysiology of depression. Drug News Perspect 2005; 18: 262–268.

130. Skolnick P, Popik P and Trullas R. Glutamate-based antidepressants: 20 years on. Trends Pharmacol Sci 2009; 30: 563–569.

131. Machado-Vieira R, Salvatore G, Diazgranados N, et al. Ketamine and the next generation of antidepressants with a rapid onset of action. Pharmacol Ther 2009; 123: 143–150.

132. Diazgranados N, Ibrahim L, Brutsche NE, et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 2010; 67: 793–802.

133. Ni N, Lee B, Liu RJ, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010; 329: 959–964.

134. Preskorn SH, Baker B, Kolluri S, et al. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with
treatment-refractory major depressive disorder. J Clin Psychopharmacol 2008; 28: 631–637.

135. Reus GZ, Stringari RB, Kirsch TR, et al. Neurochemical and behavioural effects of acute and chronic memantine administration in rats: further support for NMDA as a new pharmacological target for the treatment of depression? Brain Res Bull 2010; 81: 585–589.

136. Poleszak E, Wlaz P, Kedzierska E, et al. NMDA/glutamate mechanism of antidepressant-like action of magnesium in forced swim test in mice. Pharmacol Biochem Behav 2007; 88: 158–164.

137. Ibrahim L, Diaz Granados N, Jolkovsky L, et al. A randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder. J Clin Psychopharmacol 2012; 32: 551–557.

138. Zarate CA Jr, Mathews D, Ibrahim L, et al. A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression. Biol Psychiatry 2013; 74: 257–264.

139. Dang YH, Ma XC, Zhang JC, et al. Targeting of NMDA receptors in the treatment of major depression. Curr Pharm Des 2014; 20: 5151–5159.

140. Burgdorf J, Zhang XL, Nicholson KL, et al. GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects. Neuropsychopharmacology 2013; 38: 729–742.

141. Heresco-Levy U, Gelfin G, Bloch B, et al. A randomized add-on trial of high-dose D-cycloserine for treatment-resistant depression. Int J Neuropsychopharmacol 2013; 16: 501–506.

142. Sowa-Kucma M, Legutko B, Szewczyk B, et al. Antidepressant-like activity of zinc: further behavioral and molecular evidence. J Neural Transm (Vienna) 2008; 115: 1621–1628.

143. Jimenez-Sanchez L, Campa L, Auberson YP, et al. The role of GluN2A and GluN2B subunits on the effects of NMDA receptor antagonists in modeling schizophrenia and treating refractory depression. Neuropsychopharmacology 2014; 39: 2673–2680.

144. Wolak M, Siwek A, Szewczyk B, et al. Involvement of NMDA and AMPA receptors in the antidepressant-like activity of antidepressant drugs in the forced swim test. Pharmacol Rep 2013; 65: 991–997.

145. Kim J, Farchione T, Potter A, et al. Esketamine for treatment-resistant depression - first FDA-approved antidepressant in a new class. N Engl J Med. Epub ahead of print 22 May 2019. DOI: 10.1056/NEJMtp1903305.

146. Nakamura K and Tanaka Y. Antidepressant-like effects of aniracetam in aged rats and its mode of action. Psychopharmacology (Berl) 2001; 158: 205–212.

147. Knapp RJ, Goldenberg R, Shuck C, et al. Antidepressant activity of memory-enhancing drugs in the reduction of submissive behavior model. Eur J Pharmacol 2002; 440: 27–35.

148. Szewczyk B, Poleszak E, Sowa-Kucma M, et al. The involvement of NMDA and AMPA receptors in the mechanism of antidepressant-like action of zinc in the forced swim test. Amino Acids 2010; 39: 205–217.

149. Li X, Tizzano JP, Griffey K, et al. Antidepressant-like actions of an AMPA receptor potentiator (LY392098). Neuropsychopharmacology 2001; 40: 1028–1033.

150. Bai F, Li X, Clay M, et al. Intra- and interstrain differences in models of “behavioral despair”. Pharmacol Biochem Behav 2001; 70: 187–192.

151. Belozertsева IV, Kos T, Popik P, et al. Antidepressant-like effects of mGluR1 and mGluR5 antagonists in the rat forced swim and the mouse tail suspension tests. Eur Neuropsychopharmacol 2007; 17: 172–179.

152. Molina-Hernandez M, Tellez-Alcantara NP, Perez-Garcia J, et al. Antidepressant-like and anxiolytic-like actions of the mGlu5 receptor antagonist MTEP, microinjected into lateral septal nuclei of male Wistar rats. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 1129–1135.

153. Chaki S, Yoshikawa R, Hirota S, et al. MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity. Neuropsychopharmacology 2004; 46: 457–467.

154. Botalov AV, Van Gaalen MM, Sukhotina IA, et al. Behavioral characterization of the mGlu group II/III receptor antagonist, LY-341495, in animal models of anxiety and depression. Eur J Pharmacol 2008; 592: 96–102.

155. Klak K, Palucha A, Branski P, et al. Combined administration of PHCCG, a positive allosteric modulator of mGlu4 receptors and ACPT-I, mGlu III receptor agonist evokes antidepressant-like effects in rats. Amino Acids 2007; 32: 169–172.

156. Palucha A, Tatarczynska E, Branski P, et al. Group III mGlu receptor agonists produce...
anxiolytic- and antidepressant-like effects after central administration in rats. *Neuropsychopharmacology* 2004; 46: 151–159.

157. Palucha A, Klak K, Branski P, et al. Activation of the mGlu7 receptor elicits antidepressant-like effects in mice. *Psychopharmacology* (Berl) 2007; 194: 555–562.

158. Kang S, Li J, Bekker A, et al. Rescue of glutamate transport in the lateral habenula alleviates depression- and anxiety-like behaviors in ethanol-withdrawn rats. *Neuropsychopharmacology* 2018; 129: 47–56.

159. Chen JX, Yao LH, Xu BB, et al. Glutamate transporter 1-mediated antidepressant-like effect in a rat model of chronic unpredictable stress. *J Huazhong Univ Sci Technolog Med Sci* 2014; 34: 838–844.

160. Chen J, Yao L, Wang H, et al. Roles of glutamate transporter EAAT2 in occurrence and treatment of depression. *Chinese Pharmacological Bulletin* 2016; 32: 894–897.

161. Takahashi K, Murasawa H, Yamaguchi K, et al. Riiluzole rapidly attenuates hyperemotional responses in olfactory bulbectomized rats, an animal model of depression. *Behave Brain Res* 2011; 216: 46–52.

162. Buchan AM, Lesiuk H, Barnes KA, et al. AMPA antagonists: do they hold more promise for clinical stroke trials than NMDA antagonists? *Stroke* 1993; 24: 1148–1152.

163. Morris GF, Juul N, Marshall SB, et al. Neurological deterioration as a potential alternative endpoint in human clinical trials of experimental pharmacological agents for treatment of severe traumatic brain injuries. *Executive Committee of the International Selfotel Trial*. *Neurosurgery* 1998; 43: 1369–1372; discussion 72–74.

164. Muir KW. Glutamate-based therapeutic approaches: clinical trials with NMDA antagonists. *Curr Opin Pharmacol* 2006; 6: 53–60.

165. Ikonomidou C and Turski L. Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury? *Lancet Neurol* 2002; 1: 383–386.

166. Hardingham GE and Bading H. The yin and yang of NMDA receptor signalling. *Trends Neurosci* 2003; 26: 81–89.

167. Bertrand G, Gross R, Puech R, et al. Evidence for a glutamate receptor of the AMPA subtype which mediates insulin release from rat perfused pancreas. *Br J Pharmacol* 1992; 106: 354–359.

168. GonoI T, Mizuno N, Inagaki N, et al. Functional neuronal ionotropic glutamate receptors are expressed in the non-neuronal cell line MIN6. *J Biol Chem* 1994; 269: 16989–16992.

169. Molnar E, Varadi A, Mcllhinney RA, et al. Identification of functional ionotropic glutamate receptor proteins in pancreatic beta-cells and in islets of Langerhans. *FEBS Lett* 1995; 371: 253–257.

170. Inagaki N, Kuromi H, GonoI T, et al. Expression and role of ionotropic glutamate receptors in pancreatic islet cells. *FASEB J* 1995; 9: 686–691.

171. Weaver CD, Yao TL, Powers AC, et al. Differential expression of glutamate receptor subtypes in rat pancreatic islets. *J Biol Chem* 1996; 271: 12977–12984.

172. Leibowitz A, Boyko M, Shapira Y, et al. Blood glutamate scavenging: insight into neuroprotection. *Int J Mol Sci* 2012; 13: 10041–10066.

173. Zhumadilov A, Boyko M, Gruenbaum SE, et al. Extracorporeal methods of blood glutamate scavenging: a novel therapeutic modality. *Expert Rev Neurother* 2015; 15: 501–508.

174. Boyko M, Gruenbaum SE, Gruenbaum BF, et al. Brain to blood glutamate scavenging as a novel therapeutic modality: a review. *J Neural Transm (Vienna)* 2014; 121: 971–979.

175. Boyko M, Zlotnik A, Gruenbaum BF, et al. Pyruvate’s blood glutamate scavenging activity contributes to the spectrum of its neuroprotective mechanisms in a rat model of stroke. *Eur J Neurosci* 2011; 34: 1432–1441.

176. Boyko M, Stepensky D, Gruenbaum BF, et al. Pharmacokinetics of glutamate-oxaloacetate transaminase and glutamate-pyruvate transaminase and their blood glutamate-lowering activity in naive rats. *Neurochem Res* 2012; 37: 2198–2205.

177. O’Kane RL, Martinez-Lopez I, DeJoseph MR, et al. Na⁺-dependent glutamate transporters (EAAT1, EAAT2, and EAAT3) of the blood-brain barrier. A mechanism for glutamate removal. *J Biol Chem* 1999; 274: 31891–31895.

178. Teichberg VI, Cohen-Kashi-Malina K, Cooper I, et al. Homeostasis of glutamate in brain fluids: an accelerated brain-to-blood efflux of excess glutamate is produced by blood glutamate scavenging and offers protection from neuropathologies. *Neuroscience* 2009; 158: 301–308.

179. Zlotnik A, Gurevich B, Tkachov S, et al. Brain neuroprotection by scavenging blood glutamate. *Exp Neurol* 2007; 203: 213–220.
180. Zlotnik A, Gurevich B, Cherniavsky E, et al. The contribution of the blood glutamate scavenging activity of pyruvate to its neuroprotective properties in a rat model of closed head injury. Neurochem Res 2008; 33: 1044–1050.

181. Zlotnik A, Klin Y, Kotz R, et al. Regulation of blood L-glutamate levels by stress as a possible brain defense mechanism. Exp Neurol 2010; 224: 465–471.

182. Zlotnik A, Gruenbaum SE, Artru AA, et al. The neuroprotective effects of oxaloacetate in closed head injury in rats is mediated by its blood glutamate scavenging activity: evidence from the use of maleate. J Neurosurg Anesthesiol 2009; 21: 235–241.

183. Campos F, Rodriguez-Yanez M, Castellanos M, et al. Blood levels of glutamate oxaloacetate transaminase are more strongly associated with good outcome in acute ischaemic stroke than glutamate pyruvate transaminase levels. Clin Sci (Lond) 2011; 121: 11–17.

184. Campos F, Sobrino T, Ramos-Cabrer P, et al. High blood glutamate oxaloacetate transaminase levels are associated with good functional outcome in acute ischemic stroke. J Cereb Blood Flow Metab 2011; 31: 1387–1393.

185. Campos F, Sobrino T, Ramos-Cabrer P, et al. Neuroprotection by glutamate oxaloacetate transaminase in ischemic stroke: an experimental study. J Cereb Blood Flow Metab 2011; 31: 1378–1386.

186. Castellanos M, Sobrino T, Pedraza S, et al. High plasma glutamate concentrations are associated with infarct growth in acute ischemic stroke. Neurology 2008; 71: 1862–1868.

187. Boyko M, Melamed I, Gruenbaum BF, et al. The effect of blood glutamate scavengers oxaloacetate and pyruvate on neurological outcome in a rat model of subarachnoid hemorrhage. Neurotherapeutics 2012; 9: 649–657.

188. Biegon A, Fry PA, Paden CM, et al. Dynamic changes in N-methyl-D-aspartate receptors after closed head injury in mice: implications for treatment of neurological and cognitive deficits. Proc Natl Acad Sci U S A 2004; 101: 5117–5122.